Roivant Sciences (NASDAQ:ROIV) stock surged on Friday on positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS), an inflammatory skin condition with small bumps and broad, raised skin lesions.
BEACON Study Results Shows 100% Response
The BEACON study enrolled 31 patients randomized 3:2:2 to once daily brepocitinib 45 mg, 15 mg, or placebo with a 16-week treatment period.
The brepocitinib 45 mg arm comprised the most treatment-refractory group, with the highest percentage of patients with longstanding disease, damage, and difficult-to-treat plaque-predominant morphology.
Patients in the 45 mg arm achieved meaningful clinical improvement compared to placebo, including 100% response rates on multiple endpoints.
Brepocitinib 15 mg patients also improved considerably, with numerically similar improvement to the 45 mg arm on lower-bar endpoints and evidence of dose-dependent benefit seen on higher bar endpoints and patient-reported outcomes. Placebo patients experienced almost no improvement, consistent with the natural disease course.
On the Cutaneous Sarcoidosis Activity and Morphology Instrument – Activity score (CSAMI-A), brepocitinib …